Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 2,101–2,200 of 2,932
Opportunities in exploring chemical biology tools for better strategies against Candida albicans
Li, L., & Qiao, Y. (2025) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2025.102595 · Cited by 1
Singh, B. K., Kavita, K., Kumar, S., Maikhuri, V. K., Deo, G., Tiwari, M. K., & Maity, J. (2025) · Synlett · doi:10.1055/a-2577-0837 · Cited by 1
Inhibition of calcineurin as a strategy for biofilm control: Trichosporon spp. as a case study
da Silva, B. N., de Andrade, A. R. C., Lopes, F. E. S., Aguiar, A. L. R., Portela, F. V. M., Silva, M. L., Vasconcelos, B. M., Sidrim, J. J. C., Castelo‐Branco, D. D. S. C. M., & Cordeiro, R. D. A. (2025) · Biofouling · doi:10.1080/08927014.2025.2492712 · Cited by 1
“It is estimated that these infections are responsible for more than 1.5 million deaths annually worldwide (Bongomin et al. 2017; Strickland and Shi 2021).”
InfluentialBeneficial microbes for One Health in Canada: a review of evidence and a policy proposal
Reid, G., Allen‐Vercoe, E., Al, K. F., Burton, J. P., Daisley, B. A., Dixon, B., Mousavi, H., Sølberg, S. Ø., Peixoto, R. S., Silverman, M., et al. (2025) · FACETS · doi:10.1139/facets-2024-0182 · Cited by 1
Superficial Mycoses: A Mapping Through Bibliometric Research
Wu, J., Tang, Z., Wang, S., Qiu, Y., Nie, X., Li, C., & Wang, R. (2025) · Mycopathologia · doi:10.1007/s11046-025-00947-5 · Cited by 1
Jin, W., Yao, Y., & Lv, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-02577-1 · Cited by 1
Roncaglio, R., Bierhals, D. V., Andrade, E. F., Blan, B. D. S., Buffarini, R., von Groll, A., Basso, R. P., da Silva, P. E. A., Xavier, M. O., & Ramis, I. B. (2025) · Medical Mycology · doi:10.1093/mmy/myaf045 · Cited by 1
Love, S. L., McKeon, M. C., Vollmer, H., Paulson, J. C., Oshimura, N., Valentine, O. M., Ortiz, S. C., Hull, C. M., & Hoskins, A. A. (2025) · mSphere · doi:10.1128/msphere.00248-25 · Cited by 2
Fungal diagnostics capacity in Malaysia: A survey across 48 laboratories
Mustakim, S., Santhanam, J., Ghazali, W. N. A. M., Hassan, M., Nizam, T. M., Ibrahim, S., Ali, M. M., Kamal, R. M., Baharim, H., Ali, A. S. M., et al. (2025) · Medical Mycology · doi:10.1093/mmy/myaf056 · Cited by 1
Synergistic inhibition of pathogenic fungi by oleanolic acid combined with azoles
Chen, T., Liu, S., Yang, F., He, Z., Tang, M., Ge, L., Zhang, H., Liu, S., Zhu, X., Peng, M., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00854-25 · Cited by 6
Rodríguez, M., Toro, L. J., Firacative, C., Gómez, B. L., Rivas-Santiago, B. T., Andreu, D., Osório, J. C. C., Ramírez, G. A. T., & Muñoz, J. E. (2025) · Journal of Fungi · doi:10.3390/jof11070519 · Cited by 1
“Invasive candidiasis, an infection associated with health care settings, is one of the most frequent invasive mycoses in the world, with mortality rates between 10% and 47% [3].”
Atim, P. B., Gidudu, S., Bagaya, B. S., Kambugu, A., Najjuka, G., Winfred, A. D., Kanamwanji, B., Nabende, E., Atukunda, A., Kabazzi, J., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0327968 · Cited by 1
“These infections are common opportunistic infections associated with chronic diseases such as HIV, tuberculosis, diabetes mellitus, chronic lung diseases, cancer and asthma [4].”
Maseda, E., Peláez, T., Aguilar, G., Martín‐Loeches, I., Benítez-Cano, A., Rodríguez, A. H., Zaragoza, R., Guinea, J., Aldecoa, C., & Suárez-de-la-Rica, A. (2025) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2025.501916 · Cited by 1
Early antifungal resistance prediction based on MALDI-TOF mass spectrometry and machine learning
Duroux, D., Yang, Y., Sattler, J., Krauthammer, M. O., & Egli, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-53519-y · Cited by 6
“Fungal infections are an increasingly significant global health threat, with an estimated 1.5 million deaths annually attributed to invasive fungal diseases [1].”
InfluentialRipa, M., Galli, L., Cinque, P. M., Nozza, S., Spagnuolo, V., Din, C. T., Guffanti, M., Lolatto, R., Piromalli, G., Carletti, S., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-091113 · Cited by 1
Zhu, C., Liu, X., Gu, Y., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1660190 · Cited by 1
Bakather, O. Y., Khadrawy, S. M., Qamar, M. A., Rudayni, H. A., Alotaibi, M. T., & Imran, M. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.115301 · Cited by 1
Yang, X., Liu, T., Lei, J., Cai, W., Mai, Y., & Tang, X.-K. (2025) · Mycoses · doi:10.1111/myc.70106 · Cited by 1
Kaur, J., Kaur, K., Pathak, S., et al. (2025) · Vegetos · doi:10.1007/s42535-025-01473-x · Cited by 1
Speciation analysis of fungi by liquid atmospheric pressure MALDI mass spectrometry
Adair, L. R., Jones, I. M., & Cramer, R. (2025) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-06094-6 · Cited by 2
“Given that delayed or inappropriate antifungal therapy is strongly associated with high mortality rates, the rapid and accurate identification of fungal pathogens is critical for guiding effective treatment [5].”
Huang, H., Fang, F., Lu, W., Liu, Z., & Huang, J. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s544469 · Cited by 1
Fungal Infections in Health care
Snigdha, G. N. S., Butta, H., Mendiratta, L., & Sardana, R. (2025) · Sarvodaya International Journal of Medicine · doi:10.4103/sijm.sijm_40_25 · Cited by 1
Tang, C., Chen, C., Lv, X., Xie, Y., Li, X., Long, J., & Ye, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1648436 · Cited by 1
Agarwal, R., Biswas, K., Agrawal, A., Shankar, N. N., Kundu, S., Roy, D., Son, D., Harikishore, A., Yennamalli, R. M., Lee, D., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110743 · Cited by 3
“Both the pathogens are known to cause other forms of infections as well, and almost 2.5 million deaths occur globally every year because of fungal infections, comparable to the number of deaths from malaria or tuberculosis (3).”
InfluentialSynthesis, In Vitro and In Vivo Antifungal Activities of Novel Coumarin–Tryptophan Conjugates
Tiwari, N., Kumari, A., Sharma, S., Raghuvanshi, V., Uttam, G., Singh, V., Singh, K., & Katiyar, D. (2025) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162024607407 · Cited by 1
Organizational measures for early detection of pharyngeal mycosis using questionnaires
Miazheinikava, M. O., Ковалев, А. А., & Стома, И. О. (2025) · Health and Ecology Issues · doi:10.51523/2708-6011.2025-22-3-13 · Cited by 1
Miazheinikava, M. O., Ковалев, А. А., & Стома, И. О. (2025) · Health and Ecology Issues · doi:10.51523/2708-6011.2025-22-3-14 · Cited by 1
Gong, W., Ma, X., Wang, G., Guo, Y., Zhuo, Z., Han, C., & Wu, Y. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1669328 · Cited by 2
Medical interventions for fungal keratitis
Burn, H., FlorCruz, N. V., & Hoffman, J. J. S. L. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016304 · Cited by 4
Kalkancı, A., Bozdağ, F., Fidan, I., Tunçcan, Ö. G., Çetintepe, S. P., & ILHAN, M. N. (2025) · Journal of Fungi · doi:10.3390/jof11100718 · Cited by 1
Parra-Fariñas, R., Alonso‐Sardón, M., Solís-Sánchez, P., Alonso, B. R., Tellado, Á. G., Izquierdo, I., Belhassen‐García, M., & Pardo‐Lledías, J. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.108101 · Cited by 1
Kauser, S., Gulzar, M., Hasan, G. M., & Kumar, P. S. (2025) · Archives of Microbiology · doi:10.1007/s00203-025-04519-5 · Cited by 2
“Broader assessments also indicate that fungal diseases affect > 1 billion people worldwide and have been associated with > 1.5 million deaths in earlier estimates (Bongomin et al. 2017).”
InfluentialNovel model to predict risk of invasive fungal infection and fungal prophylaxis timing
Zuo, X., Ma, X., Zhang, M., Mao, R., & Ma, J. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02958-24 · Cited by 3
Formulation Strategies and Evaluation of Antifungal Herbal Nanogels: A Comprehensive Review
Kamble, S., & Dhenge, S. (2025) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2025.00067 · Cited by 1
Uncovering the hidden threat: WHO fungal priority pathogens in Indonesia—a systematic review
Ibrahim, S. N. M. M., Fahrudin, F. A., & Amalia, S. E. (2025) · FEMS Microbiology Letters · doi:10.1093/femsle/fnaf115 · Cited by 1
Moqaddam, Z. S., Khodavandi, P., Khodavandi, A., & Alizadeh, F. (2025) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2025.111710 · Cited by 1
Chemical Profiling of Candida albicans Growth Phases by Vibrational Spectroscopy
Pebotuwa, S., Kostoulias, X., Wood, B. R., Peleg, A. Y., & Kochan, K. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00539 · Cited by 2
Assessing the Validity and Impact of Remote Digital Image Reading in Fungal Diagnostics
Lundgren, V., Dogan, Ö., Ekwall-Larson, A., et al. (2025) · Mycopathologia · doi:10.1007/s11046-025-01012-x · Cited by 1
“The interpretation of microscopy HIV, leukemia, or organ transplant recipients [1].”
Malassezia pachydermatis Acquires Resistance to Polyenes in the Laboratory Model
Czyżewska, U., Chmielewska, S., Bartoszewicz, M., & Tylicki, A. (2025) · Pathogens · doi:10.3390/pathogens14111162 · Cited by 2
“Subtherapeutic dosing, which may promote fungal adaptation, increases the risk of resistance development [31,32].”
Cytrynbaum, E. G., & McClean, M. N. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115740 · Cited by 1
Banawas, S. (2025) · Pathogens · doi:10.3390/pathogens14121221 · Cited by 2
“The mortality rate of fungal diseases is estimated to be approximately 1.7 million annually, which is comparable to that of high-risk diseases such as tuberculosis and more than three-fold that of malaria [3,4].”
InfluentialAzab, M. S., Makhlouf, D., Ahmed, O., Hassanain, O., Shalaby, L., & Nagy, M. (2025) · Personalized Medicine · doi:10.1080/17410541.2025.2592525 · Cited by 1
Gad, M. A., Zrieq, R. M., Alsaqri, S., Alsaif, B. S., Alazzeh, A. Y., Marouf, M. A., & Fawzy, M. E. (2025) · Environmental Sciences Europe · doi:10.1186/s12302-025-01267-7 · Cited by 1
“Indeed, more than 300 million people are estimated to suffer from serious fungal infections annually, with over 1.5 million deaths [26].”
InfluentialNationwide epidemiology of candidiasis in Panama, 2010–2020
Arana, I. C., Añino, Y., Murillo, D., & Ramírez‐Camejo, L. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-27218-z · Cited by 2
Synthesis and Biological Activity of Azidomethyl Derivatives of Pyridoxine and 3-Hydroxypyridine
Platonova, E. A., Khaziev, R. M., Lisovskaya, S. A., Bondar, O. V., Mukhametova, A. D., Kazakova, R. R., Vafina, R. M., Grishaev, D. Y., Gnezdilov, O. I., Romanova, E. I., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606143 · Cited by 1
Kane, A., Lai, F., Rothwell, J. G., Dinh, T. T. H., Campbell, L. T., Cain, A. K., Hibbs, D. E., Hanrahan, J. R., & Carter, D. J. (2025) · mBio · doi:10.1128/mbio.03199-25 · Cited by 2
“Non-fatal mycoses also place a significant burden on public health, and it is estimated that more than one billion people worldwide are currently affected with a dermato phytic infection of the skin, nail, or hair, which can be uncomfortable and cosmetically disfiguring (3).”
Santiago, M. G., Costa, D. M. A., Vilela, R., Mendoza, A. L., & Goulart, G. (2025) · Animal Diseases · doi:10.1186/s44149-025-00208-4 · Cited by 2
“In addition to sporotrichosis, other fungal and fungal-like infections have been studied and are responsible for an annual mortality rate of 1.5 million persons (Bongomin et al. 2017).”
InfluentialYuan, Y., Zhou, Y., Zhou, Y., Ye, R., Lu, J., Wang, Y., Wei, F., He, F., Yu, H., & Wang, Y. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05373-5 · Cited by 2
Real-world experience with rezafungin for the treatment of biofilm-forming Candida infections
Albanell‐Fernández, M., Soriano, À., Herrera, S., Tuset, M., Arranz, N., Deckers, C., & Honoré, P. M. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2604475 · Cited by 3
Candida albicans -induced ubiquitination of EGFR reveals novel host–fungal interaction pathways
Lortal, L., Griffiths, J. S., Priest, E. L., Kempf, A., Paulin, O. K. A., Ponde, N. O., Tsavou, A., Wickramasinghe, D. N., Donkin, A. J., Lyon, C. M., et al. (2026) · mBio · doi:10.1128/mbio.03448-25 · Cited by 3
Zhang, W., Chen, J., Fang, M., Song, M., Gao, Z., Hao, J., Xu, Z., Li, X., Zheng, S., Chang, W., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03455 · Cited by 1
Soto-Debrán, J. C., Sánchez, F. J., Calvo-López, A. B., Alguacil-Cuéllar, L., Hrynzovska, A., Mellado, E., dos Santos, S. G., Alcázar‐Fuoli, L., & Alastruey‐Izquierdo, A. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1722314 · Cited by 5
“…pose a significant global health burden, affecting over one billion individuals and contributing to an estimated 3.8 million deaths annually, of which 2.5 million are directly attributable to invasive fungal infections (Bongomin et al., 2017; Brown et al., 2012; Seagle et al., 2021; Denning, 2024).”
InfluentialThe effectiveness of antifungal drugs in dermatomycosis: a systematic review with network analysis
Samtsov, A. V., Khairutdinov, V. R., & Gorbunov, Y. G. (2026) · Vestnik dermatologii i venerologii · doi:10.25208/vdv16935 · Cited by 1
Balkrishna, A., Gupta, L., Singh, R., Varshney, Y., Dev, R., Nain, P., Lochab, S., & Varshney, A. (2026) · Future Foods · doi:10.1016/j.fufo.2026.100940 · Cited by 1
Yu, G., Jiang, K., Chen, W., Tan, T., & Cong, L. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07096-4 · Cited by 1
“An estimated one billion people worldwide have skin, nail, or hair fungal infections, tens of millions experience mucosal candidiasis, and over 150 million suffer from severe, often life-threatening fungal diseases [13].”
Stella, M. M., Sally, G. V., Clarista, O., Surja, S. S., Kurniawan, S. V., & Arieselia, Z. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00032 · Cited by 1
Chen, F., Ye, Y., Yao, Y., He, J., Yu, X., Zhang, R., Ailifeire, H., Luo, C., Yao, K., Tang, X., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04088-9 · Cited by 2
“Fungal diseases cause over 1.5 million deaths and affect more than a billion people worldwide [4].”
InfluentialMuszbek, N., Angdembe, A., García‐Vidal, C., Bielicka, I., Abrams, K. R., Tolley, K. H., Ruhnke, M., Lebmeier, M., Hawkins, N., Manamley, N., et al. (2026) · Mycoses · doi:10.1111/myc.70148 · Cited by 4
Holt, C. J. D., Williams, C. C., & Usher, J. (2026) · Journal of Medical Microbiology · doi:10.1099/jmm.0.002127 · Cited by 1
“Fungal infections are a significant global health concern, causing over 1.5 million deaths annually [1].”
InfluentialHelminth Immune Modulation and Invasive Fungal Infections in Sub-Saharan Africa
Galindo, L. F., de Armas, Y., Pérez-Gómez, H. R., & Calderón, E. J. (2026) · Journal of Fungi · doi:10.3390/jof12020160 · Cited by 2
Structural barriers to antifungal drug development
Galgóczy, L. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1797104 · Cited by 4
“GAFFI advocates for wider availability of essential antifungal medicines, including amphotericin B, fl ucytosine, and itraconazole, whose access remains inconsistent in many low-and middle-income countries despite their inclusion on the WHO Essential Medicines List (Bongomin et al., 2017).”
Epidemiology of Aspergillosis Diagnoses in US Adults Using a National EHR Database, 2013–2023
Bustamante, B. L. M., Martinez, E. G., Lee, A., Kane, N. J., Camponuri, S. K., Reynolds, R. M., Snow, T. T., Bartels, J., Hoffman, M. A., White, T. C., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag094 · Cited by 6
“Global estimates suggest 250 000 cases of invasive aspergillosis and > 3 million cases of chronic pulmonary aspergillosis annually [8, 9].”
Rodrigues, D. S., Cabral, V. P. D. F., Moreira, L. E. A., Ferreira, T. L., Sá, L. G. D. A. V., da Silva, C. R., Neto, J. B. D. A., Cavalcanti, B. C., Magalhães, I. L., de Moraes, M. O., et al. (2026) · Mycologia · doi:10.1080/00275514.2026.2616853 · Cited by 1
“…as HIV/AIDS (human immunodeficiency virus/acquired immunodeficiency syndrome) patients, organ transplant recipients, or neoplastic disease patients, among others (Bongomin et al. 2017; Fang et al. 2023; Lass-Flörl and Steixner 2023), increasing the susceptibility to opportunistic fungal infections.”
Harley, B. K., Asamoah, T. D., Amengor, C. D. K., Yeboah, A. A., Kortei, N. K., & Eghan, P. (2026) · Scientifica · doi:10.1155/sci5/4558387 · Cited by 1
Coenzyme A metabolism in fungi: a new frontier in antifungal therapy
Choi, J., Chiang, A., & Mamoun, C. B. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00307-25 · Cited by 1
“…from superficial local infections to more severe, life-threatening invasive disease, with recent global burden analyses estimating ~6.5 million serious invasive fungal infections annually, resulting in ~3.8 million deaths, of which ~2.5 million are directly attributable to fungal disease (1, 2).”
InfluentialOutbreak of Kodamaea ohmeri fungemia in neonates: case series and literature review
Lou, K., Zhou, X., Xu, Y., Li, Y., Kang, W., Zhang, G., Li, J., Wang, T., Gao, H., Chen, X., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1810513 · Cited by 2
Negi, P., Verma, N., Rishi, P., Multani, K., Sharma, M., Kumari, S., & Raj, K. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04864-z · Cited by 1
Tan, C., Wu, A., & Li, C. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11005-x · Cited by 1
“Globally, over 300,000 cases of IA occur annually, predominantly among immunocompromised individuals [13].”
Salmanton-Garcia, J., Lagrou, K., Lanternier, F., et al. (2026) · Medical Mycology · doi:10.1093/mmy/myag037 · Cited by 1
Chen, Y., Tang, X., Lu, S., Guo, L., Wang, L., Min, L., Niu, T., & Zhou, Y. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03384-25 · Cited by 1
Bai, Y., Wei, M., Liu, J., Chen, X. T., Li, G. B., & Guo, Y. (2026) · The Clinical Respiratory Journal · doi:10.1111/crj.70186 · Cited by 3
Genotype–Phenotype Relationships in Azole-Resistant Aspergillus: Two Sides of the Same Coin
van Haren, M. H. I., Melchers, W. J. G., Zhang, J., Dellière, S., Bii, C. C., Stanford, F. A., Voetz, M., White, P. L., Dyer, P. S., Pas, S. D., et al. (2026) · Journal of Fungi · doi:10.3390/jof12040290 · Cited by 1
“Fungal infections represent a rapidly escalating global human health threat, imposing substantial morbidity, mortality and subsequent economic burdens [1].”
Rivera-Yañez, N., Hernández-Sánchez, K. M., Hernández-Rosas, N. A., Francisco-Cruz, L., Nieto-Yáñez, Ó., Ortega, C. C. B., Pozo‐Molina, G., Méndez-Catalá, C. F., Méndez‐Cruz, A. R., Ruiz-Hurtado, P. A., et al. (2026) · Journal of Fungi · doi:10.3390/jof12050301 · Cited by 1
“It is estimated that approximately 1.5 million people die annually from fungal infections [19], with Candida albicans being the most prominent culprit, accounting for around 40% of deaths [20,21].”
InfluentialPlatelet‐Rich Fibrins as Local Drug‐Delivery Carriers
El‐Sayed, K. M. F., & Dörfer, C. E. (2026) · Journal of Periodontal Research · doi:10.1111/jre.70114 · Cited by 1
Hasan, M. S., Sakib, S. I., Singdha, T. R., & Liton, M. A. K. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146523 · Cited by 1
Mitra, S. (2026) · Future Microbiology · doi:10.1080/17460913.2026.2671628 · Cited by 2
Mahesh, N., Harith, A., Melge, A. R., Nandini, A., Madhavan, A., Abhinand, K., Prakash, P. Y., Nair, B. G., Kumar, G. B., & Haripriyan, J. (2026) · ACS Omega · doi:10.1021/acsomega.5c12490 · Cited by 2
Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance
Arana, L., Guridi, A., Sevillano, E., Tamayo, E. H., Eraso, E., Alkorta, I., & Maté, I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104487 · Cited by 2
Empowering fungal infection research with single-cell RNA sequencing
Tóth, R., Cabarrubias, F. R., Czimmerer, Z., Vecsernyes-Nagy, K., & Gácser, A. (2026) · Communications Biology · doi:10.1038/s42003-026-10304-x · Cited by 2
“500 000 cases and mortality rates up to 30% 49,65 .”
Fungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden
Baral, B. (2026) · ChemFoodChem · doi:10.1002/cfch.70026 · Cited by 2
Emerging opportunistic yeast infections – literature review
Мирчевска, Г. (2025) · Archives of Public Health · doi:10.3889/aph.2025.6546 · Cited by 3
Lung Microbiome Diversity, Infection Dynamics, and Microbe‐Mediated Cross‐Protection
Arooj, S., Zubair, A., Batool, S. Z., Niaz, G., Ali, M., Waheed, Y., Elsharkawy, E. R., & Afghan, N. (2026) · MicrobiologyOpen · doi:10.1002/mbo3.70349 · Cited by 1
“The new findings demonstrate that most of the fungal infections of the lungs cause 1.5 million deaths each year globally and contribute to more than a billion infections overall (Bongomin et al. 2017).”
InfluentialHuman keratinocytes and fibroblasts coordinate early cutaneous innate defenses against Candida auris
Seiser, S., Brezovec, H., Penninger, P., Phan-Canh, T., Moser, D., Assen, F. P., Ayub, T., Rademacher, F., Gläser, R., Cerbu, D., et al. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.06.1279 · Cited by 2
Deptuła, P., Chmielewska-Deptuła, S. J., Spałek, J., Kaliniak, S., Okła, S., & Bucki, R. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119705 · Cited by 1
Tam, W. Y. J., Tsui, C. K. M., Beardsley, J., & Barrs, V. R. (2026) · Fungal Biology Reviews · doi:10.1016/j.fbr.2026.100501 · Cited by 2
Squitieri, D., Massaro, F., Mariotti, M., Cacaci, M., Borocci, S., Porcelli, F., Buonocore, F., Bugli, F., & Sanguinetti, M. (2026) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-026-13929-4 · Cited by 1
“As a consequence of this phenomenon, the annual number of deaths due to fungal infections has increased significantly, from 1.6 million per year globally in 2017 to 3.75 million in 2023, with 2.55 million directly attributable to fungal disease (Bongomin et al. 2017; Denning 2024).”
InfluentialAbreu‐Pereira, C. A., de Annunzio, S. R., Pereira, A. L. G., Barbugli, P. A., Vergani, C. E., & Pavarina, A. C. (2026) · ACS Omega · doi:10.1021/acsomega.6c01470 · Cited by 2
Jain, N., Kaul, S., Verma, R., Triveni, Jangde, K. K., Garg, U., Mishra, D. K., Nagaich, U., & Elella, M. H. A. (2026) · Marine Drugs · doi:10.3390/md24070249 · Cited by 1
Colombo, A. L., Magri, M. M. C., Carlesse, F. A. D. M. C., Falci, D. R., Garnica, M., Santos, D. W. D. C. L., Queiroz‐Telles, F., & Pasqualotto, A. C. (2026) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2026.105946 · Cited by 2
“7,12 There is a shortage of population-based studies conducted in Brazil, but several laboratory-based surveys of candidemia published along the last 4-years suggest that the incidence rates of candidemia in Brazil varies from 1.0 ‒ 3.4 13-15 Different authors have reported a substantial increase…”
InfluentialPasqualotto, A. C., Berrío, I., Ortíz, B., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73165-2 · Cited by 1
“Invasive fungal diseases (IFD) remain a major public health concern worldwide, with particularly severe impact in low-and middle-income countries, notably in Latin America and the Caribbean (LAC) 1,2 .”
Host Immune Responses to Pathogenic Fungi and Contemporary Therapeutic Strategies
Shallal, A. F., Razaq, C. H., Ahmed, A. S., Ahmed, S. S., Eyüpoğlu, V., & Salman, R. S. (2026) · Journal of Mycology and Truffle · doi:10.65999/mycotruffle.2026.26 · Cited by 1
Zeoli, A., Shieh, C., Bloch, K. C., Tao, L., Mainor, A., Cimino, C., Zeches, B., & Chiang, A. D. (2026) · ASM Case Reports · doi:10.1128/asmcr.00033-26 · Cited by 2
George, R., Pradeep, H. G., Mana, N. A., Raj, N., Praveen, P., Harish, R. P., Mahesh, N., Renuka, D., Nair, B. G., Kumar, G. B., et al. (2026) · Journal of Fungi · doi:10.3390/jof12080620 · Cited by 2
“The diagnosis and treatment of IFDs are challenged by limited access to quality diagnostics and inadequate treatment options as well as the emergence of antifungal resistance in many healthcare settings [3].”
Dimopoulou, G., Papadoulakis, M., Premetis, I., Papachristou, K., & Magira, E. E. (2026) · Journal of Fungi · doi:10.3390/jof12090629 · Cited by 2
“Large population-based studies have reported incidence rates ranging from 3 to 5 cases per 100,000 persons annually in the general population, corresponding to approximately 1–2% of ICU admissions [14,15].”
Ceballos-Garzón, A., Beltrán, N., Saenz, V., Pescador, L.-A., Josa, D. F., Rodriguez-Bobadilla, A., Rodriguez, L.-F., Quintero-Munoz, R., Gutierrez, I.-F., Torres-Navarrete, M. P., et al. (2026) · Journal of Fungi · doi:10.3390/jof12090640 · Cited by 1
“Invasive fungal infections (IFIs) pose a persistent and major challenge to global health, associated with substantial morbidity, mortality, and economic burden [1,2].”
The burden of serious fungal disease in the UK – infections with “rare” organisms
Borman, A. M., Székely, A., Palmer, M. D., Fraser, M., Patterson, Z., & Johnson, E. M. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.10.010 · Cited by 1
Beatrix Potter, Author, Naturalist, Mycologist
Breedlove, B. (2019) · Emerging infectious diseases · doi:10.3201/eid2509.ac2509 · Cited by 2
Alcántara-Mojica, A., Delhaès, L., Ramírez‐Corona, F., et al. (2019) · Gaceta Médica de México · doi:10.24875/gmm.19004675 · Cited by 1
Superficial Fungal Infections: Clinical Practices and Management in Asia
Rudramurthy, S. M., & Kaur, H. (2019) · Springer eBooks · doi:10.1007/978-981-13-9459-1_15 · Cited by 1
Chen, Y. (2019) · Springer eBooks · doi:10.1007/978-981-13-9459-1_16 · Cited by 4
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.